PDB15 Clinical outcomes of dapagliflozin in patients with type 2 diabetes mellitus: A meta-analysis of randomised controlled clinical trials  by Raval, A. et al.
A240  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
of ongoing trials. We also hand-searched relevant reference lists of reviews on the 
topic of dapagliflozin published until August 2013 and contacted known experts, 
US and UK drug regulatory authorities websites/personnel, and manufacturers for 
additional trials. Results: Out of 1152 reports, 28 studies were included. Twenty-
one studies compared dapagliflozin (n, 5113) to placebo (n, 2870); among these, three 
studies also compared dapagliflozin (n, 517) to metformin (n, 449) while one study 
compared dapagliflozin (n, 400) to glipizide (n, 401). Compared to placebo, dapagli-
flozin significantly improved HbA1C (Mean difference, MD: -0.51 %, 95% CI: -0.55, 
-0.47, 21 trials, 8203 participants, P< 0.00001; I2: 56%), fasting plasma glucose (MD: 
-5.72 mg/dl, 95% CI: -6.65, -4.78, 16 trials, 4942 participants, P< 0.00001; I2: 96%), body 
weight (MD: -1.81 kg, 95% CI: -2.18, -1.43, 18 trials, 6637 participants, P< 0.00001; I2: 
72%). Similarly, compared to metformin, dapagliflozin significantly improved fasting 
plasma glucose and body weight. Importantly, dapagliflozin significantly increased 
the risk of urinary tract infections (Odds ratio, OR: 1.34, 95% CI: 1.03, 1.74, 16 trials, 
6241 participants, P= 0.03; I2: 0%), genital infections (OR: 3.51, 95% CI: 2.37, 5.18, 16 
trials, 5312 participants, P< 0.00001; I2: 0%) compared to placebo. Dapagliflozin, com-
pared to metformin also, increased the risk of genital infection (OR: 4.54, 95% CI: 2.27, 
9.1, 3 trials, 1148 participants, P< 0.00001; I2: 0%). ConClusions: Dapagliflozin sig-
nificantly improved in glycaemic control but the risk of urinary tract infection and 
genital infection raises the concerns over its use compared to existing treatment.
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objeCtives: The purpose of this study was to estimate the risk of type II dia-
betes (T2DM) in children and adolescents initiating atypical antipsychotic (AAP) 
therapy. Methods: We conducted a retrospective cohort study using a new user 
design approach. Medical and pharmacy claims data between January 1, 2007 and 
December 31, 2009 for dependents ages 4 to 18 from an employed, commercially 
insured population from across the United States were included in our study. 
Exposure to an AAP was defined as the presence of an AAP pharmacy claim with 
no observed history of receiving the medication for at least six months. We con-
structed a propensity score including variables selected based on causal diagrams 
to identify and match incident AAP users and non-users. The outcome of interest, 
new-onset T2DM, was defined based on medical and pharmacy claims. Each subject 
was followed until the date of new-onset T2DM or the end of study period. The risk 
of T2DM was evaluated in an intent-to-treat fashion using the Kaplan-Meier esti-
mator and Cox proportional hazard regression that provided hazard ratio (HR) and 
associated 95% confidence intervals (CI). The study was approved by the University 
of Kentucky Institutional Review Board. Results: Our study included 6,236 new 
users and 22,080 non-users. In this propensity score matched sample, the estimated 
risk of T2DM was twice as high in AAP users as non-users (HR 2.18; 95% CI 1.45-
3.29). The noticeable risk differences between AAP-treated and control groups began 
to appear within four months of AAP initiation and it became constant after six 
months until the end of the follow-up. ConClusions: Children and adolescents 
who were prescribed an AAP medication had a two times higher risk of developing 
T2DM within six months of initiating medication when compared to non-users. 
Our study raises questions about continued AAP use in children and adolescents.
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objeCtives: We evaluated the association between insulin dose and all-cause mor-
tality, incident major adverse cardiovascular events (MACE), and incident cancer 
in people with type 2 diabetes using insulin monotherapy. Methods: We used 
retrospective observational data from the Clinical Practice Research Datalink (CPRD) 
from 2000 onwards. Subjects with type 2 diabetes who progressed to treatment with 
insulin monotherapy were selected. The risk of progression to adverse outcomes was 
compared using the Cox proportional hazards model, introducing insulin dose as 
prescribed international units per kilogram per day as a time-dependent covariate. 
We carried out extensive sub-group analyses for differing diabetes phenotypes and 
differing analytical approaches. Results: It was possible to identify 7,589 subjects. 
Event numbers were as follows: deaths, 1,450; incident MACE, 430; incident cancers, 
548. Unadjusted event rates were 66.9 deaths per 1,000 person years, 27.6 incident 
MACE per 1,000 person years, and 30.5 incident cancers per 1,000 person years. The 
overall adjusted hazard ratios in relation to an increase in insulin dose of 1 iu/kg/
day were 1.85 (95% CI 1.69–2.03) for all-cause mortality, 1.28 (1.05–1.58) for MACE, and 
1.19 (0.99–1.42) for cancer. Findings from sub-group analyses were generally con-
sistent. ConClusions: There was an association between increasing exogenous 
insulin dose and increased risk of all-cause mortality and MACE in people with type 
2 diabetes. A possible association with cancer was less clear.
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objeCtives: When compared to non-Hispanic Whites (NHW), Mexican Americans 
(MA) in the U.S. are more likely to be diagnosed with type-2 diabetes and have diabe-
tes-related comorbidities, uncontrolled glucose and less access to medical care. This 
study sought to compare the rate of adherence to diabetes medical management 
insipidus (6%-40% transient, 0%-12.5% permanent), cerebrospinal fluid leak (1%-83%) 
and hypopituitarism (0%-79%). Radiation therapy appeared effective for secondary 
treatment (remission rate 48% vs. 27% for primary CD) with benefits observed in 
the long-term. Side effect was hypopituitarism (0%-75%). Main secondary treatment 
was BLA with success rate of 100% in reversing hypercortisolism. Complications 
included Nelson’s syndrome and lifelong need for corticosteroids replacement. 
Two studies were retrieved that evaluated efficacy of ketoconazole and cabergo-
line in small patient populations, 38 and 20 patients respectively. Combination 
of pasireotide, cabergoline and ketoconazole achieved response in 88% after 80 
days. ConClusions: TSS remains the appropriate treatment for primary CD. 
However, there appears to be lower success rates and significant complications in 
patients with persistent/recurrent disease.
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objeCtives: Bariatric surgery has been as an effective treatment for type 2 diabetes 
mellitus with body mass index above 35. However, data regarding Chinese popula-
tion in this topic are inconclusive. The aim of this study is to assess the impact 
of bariatric surgery on T2DM patients in China. Methods: PubMed, EMBASE, 
Cochrane Library, and four other Chinese databases were searched from their 
inception to July, 2013. All articles were published in Chinese or English. Statistical 
analysis was performed by RevMan 5.02 and Stata12.0, a random effects model was 
used in this meta-analysis. Results: A total of 42 relevant studies were included 
with 1,665 patients. 41 studies were before-after studies and one RCT compared 
Roux-en-Y gastric bypass with sleeve gastrectomy. At baseline, a mean age of 47 
years (52% were men), duration of T2DM from 1 month to 23 years. The mean body 
mass index (BMI) for 1,450 patients was 29.99 kg/m2. BMI, Fasting Plasma Glucose 
(FPG), hemoglobin A1c (HbA1c), insulin levels and lipids profiles were declined 
significantly postoperatively. Notably, 59% (13 of 22) study reported that HbA1c 
decreased by 2.56% and got back to normal (≤ 6.5%) after 12 months. Overall, 64.6% 
of subjects were in remission (complete or partial remission); diabetes was resolved 
or improved in 90.9% of patients. Weight loss and metabolic parameters had some 
differences among surgery procedures, gastric bypass was the most effective pro-
cedure, followed by gastric banding and sleeve gastrectomy. No major adverse event 
was reported in these studies. ConClusions: This meta-analysis revealed that 
bariatric surgery is an effective treatment for T2DM and dyslipidemia in patients 
with BMI＜35. However, results were limited to short-term follow up, more high qual-
ity studies will necessary for compare different surgical procedures and long-term 
efficacy and safety in the future.
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objeCtives: Diabetes Mellitus (DM) affects approximately 371 million people 
worldwide. 37 million are in Latin America. Glycemic control is the key to prevent 
diabetes-related complications. Using the meter may prevent negative effects to the 
patient´s health and the disease cost. The objective was to examine if self-monitor-
ing of blood glucose (SMBG) is worthwhile, in terms of glycemic control, HbA1c levels 
reduction and associated complications in diabetes patients treated with insulin in 
Latin America. Methods: Data regarding the burden of DM and the value of SMBG 
in Latin America was obtained through literature search of databases including 
PubMed, the Cochrane Library, AHRQ and NICE. The intervention was SMBG with 
meter and test strips. Evidence synthesis of all studies that met the inclusion criteria 
was conducted through narrative review. Results: Two RCTs presented statistically 
significant findings indicating HbA1c level reductions of at least 1% (1.37-2.26%) in 
the SMBG group. A multinational survey found significant benefit of SMBG in data 
from 10,000 patients. Patients who practiced SMBG had a 2-3 fold increase in the 
odds of reaching HbA1c targets (< 7%). A Brazilian study found that SMBG with 
intensive insulin therapy reduces HbA1c by 1.82% compared to 0.66% in the con-
trol group. A survey of 1,000 T2DM patients in Mexico found that intensified SMBG 
demonstrated more influence on HbA1c than demographic information, carbohy-
drate consumption, amount of exercise, BMI or insulin use alone. ConClusions: 
Evidence supports SMBG’s clinical benefits in insulin-depended diabetic patients, 
with all studies reporting positive findings that indicated SMBG is related to a 
decreased HbA1c level, glycemic control, and other clinical outcomes. The SMBG can 
be an important component in the control of DM, which is projected to be increased 
to 552 million people globally by 2030. This review found both global and Latin 
American specific evidence to support SMBG for insulin using diabetes patients.
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objeCtives: To assess the clinical outcomes of dapagliflozin for type 2 diabetes 
mellitus. Methods: Randomized controlled trials of ≥ 12 weeks of duration on 
dapagliflozin compared to placebo or another antidiabetic agents in patients with 
type 2 diabetes mellitus were searched using databases from inception to August 
2013: The Cochrane Library, Ovid MEDLINE, EMBASE, Web of Science and databases 
